<DOC>
	<DOCNO>NCT00237497</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Ramelteon , daily ( QD ) , compare placebo Zopiclone adults chronic insomnia</brief_summary>
	<brief_title>Safety Efficacy Ramelteon Adults With Chronic Insomnia</brief_title>
	<detailed_description>A vast majority people affect chronic insomnia western world . Several study look estimate 30 % 48 % general population affect time life form insomnia go several month , one third describe severely affected . Daytime symptoms insomnia include tiredness , lack energy , difficulty concentrating , irritability . Recent epidemiologic research focus quality life identify significant insomnia-related condition relate work productivity , health care utilization , risk depression . Insomnia associate diminished work output , absenteeism , great rate accident . This study examine effect ramelteon balance/postural stability Night 14 peak plasma concentration level , compare placebo use zopiclone reference arm .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>Men woman age 18 64 year , inclusive . Capable understand willing comply protocol fully understand sign inform consent document screen prior studyrelated procedure perform . In addition , subject meet follow studyspecific criterion : Chronic insomnia define : A complaint difficulty initiate maintain sleep nonrestorative sleep last least 3 month . The sleep disturbance ( associate daytime fatigue ) cause clinically significant distress impairment social , occupational , important area function . The disturbance occur exclusively course narcolepsy , breathe related sleep disorder , circadian rhythm sleep disorder parasomnia . The sleep disturbance occur exclusively course another mental disorder ( eg , major depressive disorder , generalize anxiety disorder , delirium ) . The disturbance due direct physiological effect substance ( eg , drug abuse , medication ) general medical condition . Based sleep history , subjective sleep latency ( sSL ) ≥45 minute . Based sleep history , subjective total sleep time ( sTST ) ≤6.5 hour . Based sleep history , mean LPS ≥20 minute 2 consecutive screen night neither night &lt; 15 minute . Based sleep history , habitual bedtime 10:00 PM 1:00 AM . Able stand eye close , arm side foot apart hip width least 1 minute take step . A body mass index ( BMI ) 18 34 , inclusive . Used pharmacological assistance sleep 0 4 time per week last 3 month . Agreed discontinue use pharmacological sleep aid 1 week prior dose singleblind study medication throughout entire duration study . Women childbearing potential nonpregnant nonlactating appropriate birth control ( barrier method , hormonal contraceptive , and/or intrauterine device ) entire duration study ( woman childbearing potential postmenopausal 1 year history hysterectomy and/or bilateral oophorectomy ) . A known hypersensitivity ramelteon , zopiclone related compound , include melatonin melatonin related compound . Participated investigational study and/or take investigational drug within 30 day 5 halflives prior first night singleblind study medication ( whichever longer ) . Had sleep schedule change require employment ( eg , shift worker ) within 3 month prior first night singleblind study medication , fly across great 3 time zone within 7 day prior screen . Participated weightloss program substantially alter exercise routine within 30 day prior first night singleblind study medication . A history , currently , condition would affect balance : Orthostatic hypotension . Dizziness . Vertigo , benign paroxysmal positional vertigo . A history seizure , sleep apnea , chronic obstructive pulmonary disease , restless leg syndrome , periodic leg movement syndrome , fibromyalgia . A history psychiatric disorder ( include anxiety , depression , mental retardation , cognitive disorder , bipolar illness schizophrenia ) within past 6 month . A history drug addiction drug abuse within past 12 month . A history alcohol abuse within past 12 month regularly consume 14 alcoholic drink per week consume alcoholic drink within 24 hour polysomnography visit . A current significant neurological ( include cognitive psychiatric disorder ) , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematological , metabolic disease , unless currently control stable protocolallowed medication 30 day prior first night singleblind study medication . Used tobacco product nightly awakening . Used melatonin , drug supplement know affect sleep/wake function within 1 week 5 halflives drug ( whichever longer ) prior first day singleblind study medication . Used central nervous system ( CNS ) medication within 1 week 5 half life drug ( whichever longer ) prior first day singleblind study medication . Intended continue take disallowed medication prescription medication , counter ( OTC ) herbal medication know affect sleep/wake function otherwise interfere evaluation study medication . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory test . A positive urine drug screen include alcohol screen positive breathalyzer test checkin . An apnea hypopnea index ( per hour sleep ) &gt; 10 see PSG , first night PSG screening . Periodic leg movement arousal index ( per hour sleep ) &gt; 10 see PSG , first night PSG screening . Any additional condition ( ) investigator 's opinion would ( ) affect sleep/wake function , ( b ) prohibit subject completing study , ( c ) best interest subject . Had low limb prosthetics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>Center Pressure</keyword>
	<keyword>Postural Sway</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Balance Stability</keyword>
</DOC>